← All trials
NCT04801095
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 14, 2021
- Primary completion
- Aug 8, 2025
- Completion date
- Aug 8, 2025
- First posted
- Mar 16, 2021
- Last posted
- Aug 9, 2021
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Wellmarker BioLead sponsor
- CovanceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.